Involvement of NK cells in IL-28B-mediated immunity against influenza virus infection

Journal of Immunology

Volumn 199, Issue 3, 2017, Pages 1012-1020

  Wang, Yanshi ^a   Li, Tingting ^a   Chen, Yongyan ^a   Wei, Haiming ^a   Sun, Rui ^a,b   Tian, Zhigang ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD27 ANTIGEN; INTERLEUKIN 28B; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; CYTOKINE; IMMUNOGLOBULIN RECEPTOR; INTERFERON-LAMBDA PROTEIN, MOUSE; KLRG1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA; INFLUENZA A VIRUS; LIVER; LUNG; LUNG LAVAGE; MACROPHAGE; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; STAINING; VIRUS DETECTION; VIRUS STRAIN; ANIMAL; CELL DIFFERENTIATION; COCULTURE; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; LUNG ALVEOLUS MACROPHAGE; METABOLISM; ORTHOMYXOVIRUS INFECTION; PHYSIOLOGY; VIROLOGY;

ANIMALS; ANTIGENS, CD11B; ANTIGENS, CD27; CELL DIFFERENTIATION; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; KILLER CELLS, NATURAL; LIVER; LUNG; MACROPHAGES, ALVEOLAR; MICE; ORTHOMYXOVIRIDAE INFECTIONS; RECEPTORS, IMMUNOLOGIC; SPLEEN;

EID: 85026229841     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1601430     Document Type: Article

References (66)

1. Kotenko, S. V., G. Gallagher, V. V. Baurin, A. Lewis-Antes, M. Shen, N. K. Shah, J. A. Langer, F. Sheikh, H. Dickensheets, and R. P. Donnelly. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4: 69-77
2. Sheppard, P., W. Kindsvogel, W. Xu, K. Henderson, S. Schlutsmeyer, T. E. Whitmore, R. Kuestner, U. Garrigues, C. Birks, J. Roraback, et al. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4: 63-68
3. Lasfar, A., A. Lewis-Antes, S. V. Smirnov, S. Anantha, W. Abushahba, B. Tian, K. Reuhl, H. Dickensheets, F. Sheikh, R. P. Donnelly, et al. 2006. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res. 66: 4468-4477
4. Sommereyns, C., S. Paul, P. Staeheli, and T. Michiels. 2008. IFN-lambda (IFNlambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 4: e1000017
5. Lazear, H. M., T. J. Nice, and M. S. Diamond. 2015. Interferon-l: immune functions at barrier surfaces and beyond. Immunity 43: 15-28
6. Marcello, T., A. Grakoui, G. Barba-Spaeth, E. S. Machlin, S. V. Kotenko, M. R. MacDonald, and C. M. Rice. 2006. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131: 1887-1898
7. Egli, A., D. M. Santer, D. O'Shea, D. L. Tyrrell, and M. Houghton. 2014. The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Emerg. Microbes Infect. 3: e51
8. Maher, S. G., F. Sheikh, A. J. Scarzello, A. L. Romero-Weaver, D. P. Baker, R. P. Donnelly, and A. M. Gamero. 2008. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol. Ther. 7: 1109-1115
9. Mayer-Barber, K. D., and B. Yan. 2017. Clash of the cytokine titans: counterregulation of interleukin-1 and type I interferon-mediated inflammatory responses. Cell. Mol. Immunol. 14: 22-35
10. Baños-Lara Mdel, R., L. Harvey, A. Mendoza, D. Simms, V. N. Chouljenko, N. Wakamatsu, K. G. Kousoulas, and A. Guerrero-Plata. 2015. Impact and regulation of lambda interferon response in human metapneumovirus infection. J. Virol. 89: 730-742
11. Mordstein, M., G. Kochs, L. Dumoutier, J. C. Renauld, S. R. Paludan, K. Klucher, and P. Staeheli. 2008. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog. 4: e1000151
12. Baldridge, M. T., T. J. Nice, B. T. McCune, C. C. Yokoyama, A. Kambal, M. Wheadon, M. S. Diamond, Y. Ivanova, M. Artyomov, and H.W. Virgin. 2015. Commensal microbes and interferon-l determine persistence of enteric murine norovirus infection. Science 347: 266-269
13. Nice, T. J., M. T. Baldridge, B. T. McCune, J. M. Norman, H. M. Lazear, M. Artyomov, M. S. Diamond, and H. W. Virgin. 2015. Interferon-l cures persistent murine norovirus infection in the absence of adaptive immunity. Science 347: 269-273
14. Eslam, M., A. M. Hashem, R. Leung, M. Romero-Gomez, T. Berg, G. J. Dore, H. L. Chan, W. L. Irving, D. Sheridan, M. L. Abate, et al; International Hepatitis C Genetics Consortium (IHCGC). 2015. Interferon-l rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat. Commun. 6: 6422
15. Hong, S. H., O. Cho, K. Kim, H. J. Shin, S. V. Kotenko, and S. Park. 2007. Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res. 126: 245-249
16. Pagliaccetti, N. E., and M. D. Robek. 2010. Interferon-lambda in the immune response to hepatitis B virus and hepatitis C virus. J. Interferon Cytokine Res. 30: 585-590
17. Ge, D., J. Fellay, A. J. Thompson, J. S. Simon, K. V. Shianna, T. J. Urban, E. L. Heinzen, P. Qiu, A. H. Bertelsen, A. J. Muir, et al. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401
18. Liu, B., I. McGilvray, and L. Chen. 2015. IFN-l: a new class of interferon with distinct functions-implications for hepatitis C virus research. Gastroenterol. Res. Pract. 2015: 796461
19. Hruska, M., X. Wang, P. Chan, A. Ahmad, J. Freeman, M. A. Horga, J. Hillson, V. Kansra, and J. C. Lopez-Talavera. 2015. Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 2: exposure-response analyses for efficacy and safety variables. J. Clin. Pharmacol. 55: 73-80
20. Megjugorac, N. J., G. E. Gallagher, and G. Gallagher. 2009. Modulation of human plasmacytoid DC function by IFN-lambda1 (IL-29). J. Leukoc. Biol. 86: 1359-1363
21. Liu, B. S., H. L. Janssen, and A. Boonstra. 2011. IL-29 and IFNa differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFNg receptor expression. Blood 117: 2385-2395
22. de Groen, R. A., A. Boltjes, J. Hou, B. S. Liu, F. McPhee, J. Friborg, H. L. Janssen, and A. Boonstra. 2015. IFN-l-mediated IL-12 production in macrophages induces IFN-g production in human NK cells. Eur. J. Immunol. 45: 250-259
23. Mennechet, F. J., and G. Uzé. 2006. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 107: 4417-4423
24. Egli, A., D. M. Santer, D. O'Shea, K. Barakat, M. Syedbasha, M. Vollmer, A. Baluch, R. Bhat, J. Groenendyk, M. A. Joyce, et al. 2014. IL-28B is a key regulator of B- and T-cell vaccine responses against influenza. PLoS Pathog. 10: e1004556
25. Misumi, I., and J. K. Whitmire. 2014. IFN-l exerts opposing effects on T cell responses depending on the chronicity of the virus infection. J. Immunol. 192: 3596-3606
26. Grégoire, C., L. Chasson, C. Luci, E. Tomasello, F. Geissmann, E. Vivier, and T. Walzer. 2007. The trafficking of natural killer cells. Immunol. Rev. 220: 169-182
27. Strauss-Albee, D. M., and C. A. Blish. 2016. Human NK cell diversity in viral infection: ramifications of ramification. Front. Immunol. 7: 66
28. Peng, H., E. Wisse, and Z. Tian. 2016. Liver natural killer cells: subsets and roles in liver immunity. Cell. Mol. Immunol. 13: 328-336
29. Sun, C., H. Sun, C. Zhang, and Z. Tian. 2015. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cell. Mol. Immunol. 12: 292-302
30. Stein-Streilein, J., M. Bennett, D. Mann, and V. Kumar. 1983. Natural killer cells in mouse lung: surface phenotype, target preference, and response to local influenza virus infection. J. Immunol. 131: 2699-2704
31. Ennis, F. A., A. Meager, A. S. Beare, Y. H. Qi, D. Riley, G. Schwarz, G. C. Schild, and A. H. Rook. 1981. Interferon induction and increased natural killer-cell activity in influenza infections in man. Lancet 2: 891-893
32. Culley, F. J. 2009. Natural killer cells in infection and inflammation of the lung. Immunology 128: 151-163
33. Liu, F., Y. Song, and D. Liu. 1999. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6: 1258-1266
34. van der Sluijs, K. F., L. J. van Elden, M. Nijhuis, R. Schuurman, J. M. Pater, S. Florquin, M. Goldman, H. M. Jansen, R. Lutter, and T. van der Poll. 2004. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J. Immunol. 172: 7603-7609
35. Li, T., J. Wang, Y. Wang, Y. Chen, H. Wei, R. Sun, and Z. Tian. 2017. Respiratory influenza virus infection induces memory-like liver NK cells in mice. J. Immunol. 198: 1242-1252
36. Snelgrove, R. J., J. Goulding, A. M. Didierlaurent, D. Lyonga, S. Vekaria, L. Edwards, E. Gwyer, J. D. Sedgwick, A. N. Barclay, and T. Hussell. 2008. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat. Immunol. 9: 1074-1083
37. Wong, K. A., and A. Rodriguez. 2008. Plasmodium infection and endotoxic shock induce the expansion of regulatory dendritic cells. J. Immunol. 180: 716-726
38. Mordstein, M., E. Neugebauer, V. Ditt, B. Jessen, T. Rieger, V. Falcone, F. Sorgeloos, S. Ehl, D. Mayer, G. Kochs, et al. 2010. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J. Virol. 84: 5670-5677
39. Zhou, K., J. Wang, A. Li, W. Zhao, D. Wang, W. Zhang, J. Yan, G. F. Gao, W. Liu, and M. Fang. 2016. Swift and strong NK cell responses protect 129 mice against high-dose influenza virus infection. J. Immunol. 196: 1842-1854
40. Waggoner, S. N., S. D. Reighard, I. E. Gyurova, S. A. Cranert, S. E. Mahl, E. P. Karmele, J. P. McNally, M. T. Moran, T. R. Brooks, F. Yaqoob, and C. E. Rydyznski. 2016. Roles of natural killer cells in antiviral immunity. Curr. Opin. Virol. 16: 15-23
41. Durbin, R. K., S. V. Kotenko, and J. E. Durbin. 2013. Interferon induction and function at the mucosal surface. Immunol. Rev. 255: 25-39
42. Svetlikova, D., P. Kabat, A. Ohradanova, J. Pastorek, and T. Betakova. 2010. Influenza A virus replication is inhibited in IFN-l2 and IFN-l3 transfected or stimulated cells. Antiviral Res. 88: 329-333
43. Hayakawa, Y., D. M. Andrews, and M. J. Smyth. 2010. Subset analysis of human and mouse mature NK cells. Methods Mol. Biol. 612: 27-38
44. Hayakawa, Y., and M. J. Smyth. 2006. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J. Immunol. 176: 1517-1524
45. Huntington, N. D., H. Tabarias, K. Fairfax, J. Brady, Y. Hayakawa, M. A. Degli- Esposti, M. J. Smyth, D. M. Tarlinton, and S. L. Nutt. 2007. NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation. J. Immunol. 178: 4764-4770
46. Mahlakõiv, T., P. Hernandez, K. Gronke, A. Diefenbach, and P. Staeheli. 2015. Leukocyte-derived IFN-α/β and epithelial IFN-l constitute a compartmentalized mucosal defense system that restricts enteric virus infections. PLoS Pathog. 11: e1004782
47. Witte, K., G. Gruetz, H. D. Volk, A. C. Looman, K. Asadullah, W. Sterry, R. Sabat, and K. Wolk. 2009. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun. 10: 702-714
48. Syedbasha, M., and A. Egli. 2017. Interferon lambda: modulating immunity in infectious diseases. Front. Immunol. 8: 119
49. Wilden, H., P. Fournier, R. Zawatzky, and V. Schirrmacher. 2009. Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by newcastle disease virus. Int. J. Oncol. 34: 971-982
50. García-Sastre, A. 2011. Induction and evasion of type I interferon responses by influenza viruses. Virus Res. 162: 12-18
51. Feeley, E. M., J. S. Sims, S. P. John, C. R. Chin, T. Pertel, L. M. Chen, G. D. Gaiha, B. J. Ryan, R. O. Donis, S. J. Elledge, and A. L. Brass. 2011. IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog. 7: e1002337
52. Backer, R., T. Schwandt, M. Greuter, M. Oosting, F. Jüngerkes, T. Tüting, L. Boon, T. O'Toole, G. Kraal, A. Limmer, and J. M. den Haan. 2010. Effective collaboration between marginal metallophilic macrophages and CD8+ dendritic cells in the generation of cytotoxic T cells. Proc. Natl. Acad. Sci. USA 107: 216-221
53. Liu, Q., Y. H. Zhou, and Z. Q. Yang. 2016. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell. Mol. Immunol. 13: 3-10
54. van Pesch, V., H. Lanaya, J. C. Renauld, and T. Michiels. 2004. Characterization of the murine alpha interferon gene family. J. Virol. 78: 8219-8228
55. Donnelly, R. P., and S. V. Kotenko. 2010. Interferon-lambda: a new addition to an old family. J. Interferon Cytokine Res. 30: 555-564
56. Jewell, N. A., T. Cline, S. E. Mertz, S. V. Smirnov, E. Flaño, C. Schindler, J. L. Grieves, R. K. Durbin, S. V. Kotenko, and J. E. Durbin. 2010. Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J. Virol. 84: 11515-11522
57. Ank, N., M. B. Iversen, C. Bartholdy, P. Staeheli, R. Hartmann, U. B. Jensen, F. Dagnaes-Hansen, A. R. Thomsen, Z. Chen, H. Haugen, et al. 2008. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J. Immunol. 180: 2474-2485
58. Ank, N., H. West, C. Bartholdy, K. Eriksson, A. R. Thomsen, and S. R. Paludan. 2006. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol. 80: 4501-4509
59. Wack, A., E. Terczynska-Dyla, and R. Hartmann. 2015. Guarding the frontiers: the biology of type III interferons. Nat. Immunol. 16: 802-809
60. Liu, J., and X. Cao. 2016. Cellular and molecular regulation of innate inflammatory responses. Cell. Mol. Immunol. 13: 711-721
61. Souza-Fonseca-Guimaraes, F., A. Young, D. Mittal, L. Martinet, C. Bruedigam, K. Takeda, C. E. Andoniou, M. A. Degli-Esposti, G. R. Hill, and M. J. Smyth. 2015. NK cells require IL-28R for optimal in vivo activity. Proc. Natl. Acad. Sci. USA 112: E2376-E2384
62. Morrison, M. H., C. Keane, L. M. Quinn, A. Kelly, C. O'Farrelly, C. Bergin, and C. M. Gardiner. 2014. IFNL cytokines do not modulate human or murine NK cell functions. Hum. Immunol. 75: 996-1000
63. Kopf, M., C. Schneider, and S. P. Nobs. 2015. The development and function of lung-resident macrophages and dendritic cells. Nat. Immunol. 16: 36-44
64. Jordan, W. J., J. Eskdale, S. Srinivas, V. Pekarek, D. Kelner, M. Rodia, and G. Gallagher. 2007. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun. 8: 254-261
65. Morrow, M. P., J. Yan, P. Pankhong, B. Ferraro, M. G. Lewis, A. S. Khan, N. Y. Sardesai, and D. B. Weiner. 2010. Unique Th1/Th2 phenotypes induced during priming and memory phases by use of interleukin-12 (IL-12) or IL-28B vaccine adjuvants in rhesus macaques. Clin. Vaccine Immunol. 17: 1493-1499
66. Koltsida, O., M. Hausding, A. Stavropoulos, S. Koch, G. Tzelepis, C. Ubel, S. V. Kotenko, P. Sideras, H. A. Lehr, M. Tepe, et al. 2011. IL-28A (IFN-l2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol. Med. 3: 348-361